Clinical trials: Multi-Drug Resistant Organisms
Vancomycin-Resistant Enterococcus, Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae, or Carbapenem-Resistant Enterobacteriaceae Colonized Subjects
VITORA: Clinical Study to Evaluate the Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointestinal Tracts Are Colonized With Multiple Drug-resistant Organisms
This randomized, open-label, clinical study aims to explore the safety and tolerability of KB109, a novel glycan, versus an observational control group on the gut microbiome in subjects whose gastrointestinal tracts are colonized…
- Trial name
- VITORA (NCT03944369)
- Testing
- KB109, No intervention
- Where
- 8 sites in United States
- Volunteers
- 3 people
- Sponsor
- Kaleido Biosciences
Intestinal Multi-drug Resistant Organism Colonization
Further MT for Antibiotic-Resistant Bacterial Colonization
The purpose of this study is to better understand the effectiveness and safety of microbiome therapies (MT) as a treatment for patients with Multidrug Resistant Organism (MDRO) colonization after an infection.
- Trial name
- FAIR (NCT05835206)
- Testing
- Microbiome Therapeutic
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Emory University
Severe Acute Malnutrition, Health Care Associated Infection
Prevention of Nosocomial Infections (CleanKids)
While the standardization of treatment protocols for Severe Acute Malnutrition (SAM) has helped to reduce historically high mortality, mortality in inpatient settings remains substantial, likely due to the severity of…
- Conditions
- Severe Acute Malnutrition, Health Care Associated Infection, Multi Drug Resistant Organisms
- Trial name
- CleanKids (NCT03360877)
- Testing
- Health-care associated infection (HCAI)
- Volunteers
- 4,944 people
- Sponsor
- Epicentre
Multi-Drug Resistant Organism
Sentinel Cohort REACT
The purpose of this study is to better understand the efficacy and safety of microbiome therapies (MT) in patients with Multidrug Resistant Organism (MDRO) colonization who are admitted to Long Term Acute Care Hospitals (LTACH).
- Trial name
- NCT05780801
- Testing
- Allogeneic Microbiota in Glycerol (10%) (AMG)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Chronic Kidney Disease, Glomerular Filtration Rate
The Relationship Between Renal Functions and Multi Drug Resistant Organisms
Ventilator-associated pneumonia (VAP) is the most common nosocomial infection in patients receiving invasive mechanical ventilation (MV).
- Conditions
- Chronic Kidney Disease, Glomerular Filtration Rate, Drug Resistance
- Trial name
- NCT04833231
- Where
- Turkey (Türkiye)
- Volunteers
- 133 people
- Sponsor
- Konya Numune Hospital
Drug Resistance, Multiple, Bacterial, Cholangiopancreatography, Endoscopic Retrograde
Prevalence of Multidrug Resistant Micro-organism Carriage in Patients Undergoing an ERCP in Four Different Countries
The duodenoscopes currently used for Endoscopic Retrograde Cholangio - and Pancreaticography (ERCP) examinations are reusable and are therefore washed and disinfected after each use.
- Trial name
- PREVENT (NCT05303662)
- Testing
- Multidrug-Resistant Organisms (MDRO) testing through rectal and oral/nasal swabs, MDRO-testing duodenal aspirate, Microbiome through rectal swab
- Where
- 4 sites in United States, India and 2 more
- Volunteers
- 1,244 people
- Sponsor
- Marco J. Bruno
Infection With Multi-drug Resistant Organisms
FMT for Multidrug Resistant Organism Reversal
This proposed protocol involves the use of the fecal microbiota transplantation (FMT) to suppress or reverse colonization with multidrug resistant organisms (MDRO) in subjects with recurrent MDRO infections due to organisms of…
- Trial name
- NCT02312986
- Testing
- Fecal microbiota transplantation (FMT)
- Volunteers
- 1 people
- Sponsor
- Washington University School of Medicine
Lung-transplant Recipients, Antibiotic Prophylaxis
Antibiotic Prophylaxis in Lung-Transplant Recipients
Retrospective, monocentric observational pharmacological cohort study including all adult patients who underwent lung transplantation at IRCCS Azienda Ospedaliero-Universitaria di Bologna from 1st January 2002 to 31st August 2023.
- Trial name
- PRO-LUNG (NCT06760143)
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Multi Drug Resistant Organisms
Infection Risk Associated With Digestive MDRO Carriage in Hospitalized Patients
This study aims to evaluate the impact of digestive carriage of multidrug-resistant organisms (MDRO) on the risk of healthcare-associated infections in hospitalized adult patients.
- Trial name
- NCT07134270
- Testing
- MDRO Rectal Screening, 30-Day Telephone Follow-Up
- Where
- Romania
- Volunteers
- 400 people
- Sponsor
- Valeriu Gheorghita
Bacterial Infection, Benign Neoplasm
Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant
This randomized phase III trial studies chlorhexidine gluconate cleansing to see how well it works compared to control cleansing in preventing central line associated bloodstream infection and acquisition of multi-drug resistant…
- Conditions
- Bacterial Infection, Benign Neoplasm, Malignant Neoplasm, Methicillin-Resistant Staphylococcus Aureus Infection
- Trial name
- NCT01817075
- Testing
- Chlorhexidine Gluconate Skin Cleanser, Laboratory Biomarker Analysis, Mild Soap Skin Cleanser
- Where
- 59 sites in United States, Canada and 1 more
- Volunteers
- 177 people
- Sponsor
- Children's Oncology Group
E Coli Infection
Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia Coli
This is a prospective, observational, multicenter, case-control study.
- Trial name
- SHREC (NCT04574596)
- Testing
- no Intervention
- Where
- 13 sites in United States
- Volunteers
- 300 people
- Sponsor
- Duke University
Multi Drug Resistant Organisms, Antibiotic Resistance
Characterization of the Synergistic Antibacterial Effect of Verapamil on Bacterial Isolates From Cancer Patients
Multidrug-resistant (MDR) bacteria represent a significant global health challenge, particularly among immunocompromised populations such as cancer patients undergoing chemotherapy.
- Trial name
- NCT07505446
- Testing
- verapamil
- Volunteers
- 100 people
- Sponsor
- Assiut University
Ventilator Associated Pneumonia, Multi-antibiotic Resistance
Ventilator Associated Pneumonia by Multi-Drug Resistant Organism
Ventilator-associated pneumonia (VAP) is an infection of the pulmonary parenchyma in patients exposed to invasive mechanical ventilation for at least 48 h and is part of ICU-acquired pneumonia.
- Trial name
- VAP-MDR (NCT05549427)
- Testing
- Ventilation
- Where
- Oman
- Volunteers
- 319 people
- Sponsor
- Sultan Qaboos University
Covid19, Personal Protective Equipment
Rational Use of Personal Protective Equipment During COVID-19 Pandemic
This study aims to improve the personal protective equipment (PPE) used while treating patients with COVID-19, to protect staff and avoid cross-infection of patients.
- Trial name
- RUPERT (NCT04712045)
- Testing
- New PPE, Old PPE
- Where
- United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Infections Resistant to Multiple Drugs, Bacterial Infections
Multi-Drug Resistant Organism Network
This study is specifically designed to provide observational data which can be used to help in the design of future randomized clinical trials on both therapeutics and diagnostics for MDRO infections.
- Trial name
- MDRO Network (NCT03646227)
- Testing
- Standard of Care
- Where
- 4 sites in United States, Australia and 2 more
- Volunteers
- 6,496 people
- Sponsor
- Duke University
Pneumonia, Pneumonia - Bacterial
Derivation and Validation of the Risk Evaluation Score for Pneumonia Involving Resistant Entities (RESPIRE)
This is a single-center, non-profit observational study with two sequential phases: an initial retrospective phase followed by a prospective phase. Patients were enrolled during two consecutive, non-overlapping periods.
- Conditions
- Pneumonia, Pneumonia - Bacterial, Multi Drug Resistant, Multi Drug Resistant Organisms
- Trial name
- RESPIRE (NCT07425561)
- Testing
- RESPIRE score
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Clostridium Difficile Infection, Multi Drug Resistant Organisms
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gastrointestinal Diseases
This is a prospective, clinical, multicentre study aimed to collect biological samples and study microbiota from subjects with Clostridium Difficile (CDI), subjects affected by Multi Drug Resistant Organisms (MDRO) infection…
- Conditions
- Clostridium Difficile Infection, Multi Drug Resistant Organisms, Chronic Inflammatory Bowel Disease, Irritable Bowel Syndrome
- Trial name
- BIOMIS-Gastr (NCT04698148)
- Testing
- Biological sample collection, Questionnaire, Medical examination
- Where
- 3 sites in Italy
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Mechanically Ventilated Patients
The Effect of Uroshield on Sputum-specimen Bacterial Growth
The investigators retrospectively register the conduct of this study after its completion.
- Trial name
- NCT06729476
- Testing
- Uroshield vibrator device
- Volunteers
- 48 people
- Sponsor
- Shaare Zedek Medical Center
Resistance Bacterial
Decolonization of Gram-negative Multi-resistant Organisms (MDRO) with Donor Microbiota (FMT)
Colonization by Multiple Drug Resistant Organisms (MDROs) during patient hospitalization requires expensive isolation measures and renders the return or transfer to other departments or institutions often impossible.
- Trial name
- DEKODON (NCT04188743)
- Testing
- Allogenic FMT, Autologous FMT
- Where
- Belgium
- Volunteers
- 150 people
- Sponsor
- University Hospital, Ghent
Multi-Drug Resistant Organism Colonization
Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)
REACT is a phase two, open-label, randomized, controlled trial of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO).
- Trial name
- NCT06321536
- Testing
- Allogeneic Microbiota in Glycerol (9%) (AMG)
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Emory University